R&D channel feed

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

Last year
Deals
In Focus

Mi­rati and Am­gen un­wrap new KRAS tri­al da­ta, set­ting the stage for po­ten­tial com­bo treat­ments: #ES­MO23

Last year

Ear­ly da­ta on Dai­ichi Sankyo’s Mer­ck-part­nered ADC; As­traZeneca’s Da­to-Dxd com­bo; more from Seagen: #ES­MO23 roundup

Last year
Pharma

Roche de­tails Ale­cen­sa da­ta that may shift the drug to post-surgery ALK-pos­i­tive lung can­cer: #ES­MO23

Last year
Pharma

Pad­cev-Keytru­da sets new stan­dard in blad­der can­cer as Seagen and Astel­las move to­ward full ap­proval: #ES­MO23

Last year
Pharma

Eli Lil­ly re­veals two-year da­ta for ex­per­i­men­tal eczema treat­ment af­ter FDA road­block

Last year
Pharma
FDA+

Up­dat­ed: Am­gen spot­lights new ef­fi­ca­cy, safe­ty da­ta of mid-phase tar­latam­ab tri­al in hard-to-treat can­cer: #ES­MO23

Last year

J&J un­veils PhI­Ia da­ta of oral an­tivi­ral for dengue fever pre­ven­tion

Last year

Bris­tol My­ers un­corks pos­i­tive PhI­II read­out for sub­cu­ta­neous Op­di­vo

Last year
Pharma

Beam cuts 20% of staff, looks to part­ner on base-edit­ed CAR-T one month af­ter dos­ing first pa­tient

Last year
Cell/Gene Tx

Big Phar­mas part­ner with HBCU, with aim to cre­ate the largest African an­ces­try ge­nomics data­base

Last year
Pharma

Takeda's stem cell ther­a­py flunks PhI­II test study­ing the drug in Crohn's dis­ease

Last year

FDA ap­proves Mer­ck­'s Keytru­da for be­fore and af­ter lung can­cer surgery

Last year
FDA+

Rhythm’s drug shows 25% drop in BMI over one year for pa­tients with rare form of obe­si­ty

Last year

Up­dat­ed: ES­MO em­bar­go break leads can­cer con­fer­ence to re­lease da­ta for Bris­tol My­ers, J&J, No­var­tis, As­traZeneca

Last year
Pharma

Apel­lis’ C3 in­hibitor shows bio­mark­er im­pact in small PhII rare kid­ney dis­ease tri­al

Last year

Evelo dealt an­oth­er blow with a PhII fail, plans for strate­gic al­ter­na­tives

Last year

Ul­tragenyx to spin off com­pa­ny to de­vel­op ‘high risk, high re­turn’ gene ther­a­py for Alzheimer’s dis­ease

Last year
Startups

Ab­b­Vie’s Skyrizi helps more Crohn's pa­tients stay off steroids than J&J’s Ste­lara, PhI­II da­ta show

Last year
Pharma

Atom Bio­science rais­es $83M in Se­ries D for URAT1 in­hibitor in chron­ic gout treat­ment

Last year
Financing

Omeros drug fails a PhI­II kid­ney tri­al, stock near­ly halved

Last year

So­tio ter­mi­nates three tri­als study­ing its IL-15 su­per­ag­o­nist due to ‘in­suf­fi­cient ef­fi­ca­cy’

Last year

Biotech in Is­rael: Hold­ing on to busi­ness as usu­al amid un­cer­tain times

Last year
Startups

Sanofi’s eczema drug hits pri­ma­ry end­point in PhI­Ib tri­al, plans un­der­way for PhI­II in 2024

Last year
First page Previous page 67686970717273 Next page Last page
A service from the Financial Times